Glooko Raises $30 Million in Series D Funding

A half-dozen investors have endowed Glooko Inc. with $30 million in a Series D funding round. 

The financing was led by Health Catalyst Capital, with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet, and Mayo Clinic. Proceeds will be used to accelerate organic growth and strategic initiatives across the company’s product line of advanced digital health solutions.

“Glooko has done a remarkable job of bringing to market cutting edge digital healthcare platforms, which empower people with diabetes to better manage their disease and improve their lives. This technology enables physicians to take better care of patients with diabetes by strengthening the engagement between people with diabetes and their healthcare providers,” said Charles Boorady, founder and managing partner of Health Catalyst Capital. “As a result of Glooko’s innovations, the company has experienced rapid market adoption growing its global ecosystem to more than 7,500 clinics and has entered into partnerships with many of the world’s largest diabetes medical device companies and pharmaceutical companies as well as top healthcare systems. We look forward to supporting the company in its next phase of growth as it invests in new capabilities supporting the management of chronic care and serving even more stakeholders.”
 
This round of financing follows the most successful year in Glooko’s history, despite the global pandemic. Last year, the company’s growth included key partnerships with major healthcare systems, and extended long-term existing partnerships with several global diabetes industry leading companies such as Insulet and Novo Nordisk.
 
The new proceeds will accelerate execution of Glooko’s commercial strategy, including increasing adoption of Glooko’s remote patient monitoring platform, widening commercialization of products in clinical research and expanding into additional therapy areas.
 
“This is an unprecedented time in healthcare and technology. The demand for our platform demonstrates this sea-change. Glooko has experienced considerable growth, and this funding allows us to build on our strong momentum in providing the advanced technologies we’re known for,” said Russ Johannesson, CEO of Glooko. “Now more than ever, the healthcare industry is seeking new and smarter technologies, whether it’s for patient care or researching new therapies. I am excited to lead the team at Glooko in our mission to improve health outcomes by connecting people with diabetes and other chronic conditions with their healthcare professionals.”